How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Exosome Drug Delivery Services Market
- By Service Type: Exosome Isolation and Purification, Exosome Characterization and Analysis, Exosome Engineering and Modification, Exosome Formulation and Encapsulation, Exosome Storage and Logistics
- By Source Material: Mesenchymal Stem Cell-Derived Exosomes, Dendritic Cell-Derived Exosomes, Immune Cell-Derived Exosomes, Tumor Cell-Derived Exosomes, Plant-Derived Exosomes
- By Therapeutic Application: Oncology Drug Delivery, Neurological Disorder Treatment, Cardiovascular Disease Therapy, Inflammatory and Autoimmune Diseases, Regenerative Medicine
- By End-User: Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Research Institutes, Hospitals and Clinical Research Centers
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Exosome Isolation and Purification leads By Service Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Exosome Drug Delivery Services Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Service Type 5
Source Material 5
Therapeutic Application 5
End-User 4
Companies profiled
Codiak BioSciences
Exosome Diagnostics (a Bio-Techne brand)
Evox Therapeutics
ReNeuron Group
Capricor Therapeutics
Aruna Bio
Creative Biolabs
Hansa Biopharma
Anjarium Biosciences
PureTech Health
ExoCoBio
System Biosciences (SBI)
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Codiak BioSciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Exosome Diagnostics (a Bio-Techne brand)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Evox Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →ReNeuron Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Capricor Therapeutics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Aruna Bio
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Creative Biolabs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Hansa Biopharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Anjarium Biosciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →PureTech Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →ExoCoBio
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →System Biosciences (SBI)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Thermo Fisher Scientific
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Lonza Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Takeda Pharmaceutical Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$2,050M by 2033 · 4.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Exosome Isolation and Purification36.3
- Exosome Characterization and Analysis12.1
- Exosome Engineering and Modification13.4
- Exosome Formulation and Encapsulation19.0
- Exosome Storage and Logistics19.1
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$461.0M → $638.6M · 4.2%
Europe$321.3M → $427.8M · 3.6%
Asia Pacific$293.3M → $407.5M · 4.2%
Latin America$181.6M → $269.5M · 5.1%
Middle East and Africa$139.7M → $196.5M · 4.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →4.862026
4.882027
4.892028
4.912029
4.922030
4.912031
4.942032
4.952033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Codiak BioSciences17.6
- Exosome Diagnostics (a Bio-Techne brand)19.2
- Evox Therapeutics8.7
- ReNeuron Group10.1
- Capricor Therapeutics11.3
- Aruna Bio5.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Service Type33.5%
Source Material14.7%
Therapeutic Application14.9%
End-User37.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.9
- Europe22.1
- Asia Pacific21.0
- Latin America13.9
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Codiak BioSciences | 88 | 78 | 75 | 80 | 95 | 86 | 84 |
| Exosome Diagnostics (a Bio-Techne brand) | 70 | 86 | 82 | 83 | 81 | 88 | 82 |
| Evox Therapeutics | 70 | 79 | 69 | 70 | 83 | 74 | 74 |
| ReNeuron Group | 66 | 74 | 74 | 69 | 65 | 64 | 69 |
| Capricor Therapeutics | 75 | 69 | 60 | 72 | 62 | 74 | 69 |
| Aruna Bio | 65 | 62 | 58 | 65 | 50 | 67 | 61 |
| Creative Biolabs | 62 | 53 | 51 | 60 | 52 | 50 | 55 |
| Hansa Biopharma | 56 | 38 | 58 | 54 | 35 | 46 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Codiak BioSciences
- Exosome Diagnostics (a Bio-Techne brand)
- Evox Therapeutics
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Codiak BioSciences | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Exosome Diagnostics (a Bio-Techne brand) | ◐ | ✓ | ✓ | ◐ | ✓ | ✓ |
| Evox Therapeutics | ◐ | ◐ | − | ◐ | ◐ | ◐ |
| ReNeuron Group | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Capricor Therapeutics | ◐ | ◐ | − | ✓ | ◐ | − |
| Aruna Bio | − | − | ◐ | ◐ | − | ◐ |
| Creative Biolabs | ◐ | ◐ | − | − | − | ◐ |
| Hansa Biopharma | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Codiak BioSciences84
2Exosome Diagnostics (a Bio-Techne brand)82
3Evox Therapeutics74
4ReNeuron Group69
5Capricor Therapeutics69
6Aruna Bio61
7Creative Biolabs55
8Hansa Biopharma48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Codiak BioSciencesExosome Diagnostics (a Bio-Techne brand)
Challenger3
Strong scale, closing on the leaders.
Evox TherapeuticsReNeuron GroupCapricor Therapeutics
Contender1
Focused players with pockets of strength.
Aruna Bio
Niche2
Specialists in a single segment or region.
Creative BiolabsHansa Biopharma
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Service Type in North America, then scale across Exosome Drug Delivery Services Market — a $265M beachhead inside a $4.35B market.
Beachhead (SOM)$265Mobtainable near-term
Serviceable (SAM)$1.70Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Exosome Isolation and Purification
Best fit — highest urgency & budget in Service Type.
Economic buyer76 fit
Exosome Characterization and Analysis
Strong fit — clear ROI and a fast path to value.
End user69 fit
Exosome Engineering and Modification
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Service Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Source Material & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Therapeutic Application
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve23%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Service Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Exosome Drug Delivery Services Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified46%
Sales qualified23%
Evaluation13%
Closed-won7%
$16.5KCAC
$94KLTV
5.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Exosome Drug Delivery Services Market is a durable-growth opportunity — $8.79B by 2033, compounding at 6.5%.
TAM · 2025$5.32Btoday
TAM · 2033$8.79Bforecast
CAGR6.5%2027–2033
Cumulative$62.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.79BTotal addressable market
SAM$3.59BServiceable available market
SOM$717MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.5% CAGR
Demand compounds through 2033, outpacing GDP across Service Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Service Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.79BLarge & growingTAM by 2033 at 6.5% CAGR
$3.59BServiceable nowreachable with today’s model
$717MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.86BBear4.2% CAGR
$8.79BBase6.5% CAGR
$11.3BBull8.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Source Material optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Exosome Drug Delivery Services Market — a $4.05B market by 2033. Plan: grow share from 8.0% to 12.8%.
Market size · 2033$4.05Btotal addressable
Market CAGR4.8%2027–2033
Target share12.8%from 8.0% today
Revenue ambition$519Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 12.8% | At risk |
| Revenue | $315M | $519M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 34.5% | 44.7% | Behind |
| Customer retention | 90.4% | 94.2% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Service Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Source Material capability
A defensible second engine — invest in Source Material to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Service Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Source Material
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $66M capacity & capability investment
- Greenlight bolt-on M&A in Source Material
- Authorise North America expansion plan
- Fund R&D program for Service Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Exosome Drug Delivery Services Market conversation — a $9.92B market you can size, segment and defend in minutes.
Market size · 2033$9.92Btotal opportunity
Growth8.0%CAGR to 2033
Addressable buyers1,651+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Service Type
Goal Grow share in Service Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 2 mopayback period
$57K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Codiak BioSciencesExosome Diagnostics (a Bio-Techne brand)Evox TherapeuticsReNeuron GroupCapricor TherapeuticsAruna BioCreative BiolabsHansa Biopharma+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Exosome Drug Delivery Services Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Exosome Drug Delivery Services Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Exosome Isolation and Purification Service Market
Market size, share, segmentation and regional forecast.
$766M market · 2025 base year
View reportExosome Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportExostosin 1 Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportExotic Fruit Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportExpandable Braided Sleevin Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportExpandable Chucks Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportExpandable Interbody Fusion Cages Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportExpandable Interbody Systems Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportExpandable Microsphere Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportExpandable Military Shelters Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportExpandable Styrene Polymers Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View reportExpanded Cement Alunite Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.